Base de dados : MEDLINE Pesquisa : D06.472.699.327.700.875 [Categoria DeCS] Referências encontradas : 18411 [refinar] Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1842

ir para página

1 / 18411

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 29339530 [Au] Autor: Kasuki L; Wildemberg LE; Gadelha MR [Ad] Endereço: Neuroendocrinology Research Center/Endocrine Section and Medical SchoolHospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. [Ti] Título: MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly. [So] Source: Eur J Endocrinol;178(3):R89-R100, 2018 Mar. [Is] ISSN: 1479-683X [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: Acromegaly is associated with high morbidity and elevated mortality when not adequately treated. Surgery is the first-line treatment for most patients as it is the only one that can lead to immediate cure. In patients who are not cured by surgery, treatment is currently based on a trial-and-error approach. First-generation somatostatin receptor ligands (fg-SRL) are initiated for most patients, although approximately 25% of patients present resistance to this drug class. Some biomarkers of treatment outcome are described in the literature, with the aim of categorizing patients into different groups to individualize their treatments using a personalized approach. In this review, we will discuss the current status of precision medicine for the treatment of acromegaly and future perspectives on the use of personalized medicine for this purpose. [Mh] Termos MeSH primário: Acromegalia/tratamento farmacológico Adenoma/tratamento farmacológico Agonistas de Dopamina/uso terapêutico Adenoma Hipofisário Secretor de Hormônio do Crescimento/tratamento farmacológico Medicina de Precisão Receptores da Somatotropina/antagonistas & inibidores Somatostatina/análogos & derivados [Mh] Termos MeSH secundário: Seres Humanos Resultado do Tratamento [Pt] Tipo de publicação: JOURNAL ARTICLE; REVIEW [Nm] Nome de substância: 0 (Dopamine Agonists); 0 (Receptors, Somatotropin); 51110-01-1 (Somatostatin) [Em] Mês de entrada: 1802 [Cu] Atualização por classe: 180220 [Lr] Data última revisão: 180220 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 180118 [St] Status: MEDLINE [do] DOI: 10.1530/EJE-17-1006

2 / 18411

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28974369 [Au] Autor: Ávila-Mendoza J; Pérez-Rueda E; Urban-Sosa V; Carranza M; Martínez-Moreno CG; Luna M; Arámburo C [Ad] Endereço: Departamento de Neurobiología Celular y Molecular, Instituto de Neurobiología, Campus Juriquilla, Universidad Nacional Autónoma de México, Querétaro, Qro. 76230, Mexico. [Ti] Título: Characterization and distribution of GHRH, PACAP, TRH, SST and IGF1 mRNAs in the green iguana. [So] Source: Gen Comp Endocrinol;255:90-101, 2018 Jan 01. [Is] ISSN: 1095-6840 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: The somatotropic axis (SA) regulates numerous aspects of vertebrate physiology such as development, growth, and metabolism and has influence on several tissues including neural, immune, reproductive and gastric tract. Growth hormone (GH) is a key component of SA, it is synthesized and released mainly by pituitary somatotrophs, although now it is known that virtually all tissues can express GH, which, in addition to its well-described endocrine roles, also has autocrine/paracrine/intracrine actions. In the pituitary, GH expression is regulated by several hypothalamic neuropeptides including GHRH, PACAP, TRH and SST. GH, in turn, regulates IGF1 synthesis in several target tissues, adding complexity to the system since GH effects can be exerted either directly or mediated by IGF1. In reptiles, little is known about the SA components and their functional interactions. The aim of this work was to characterize the mRNAs of the principal SA components in the green iguana and to develop the tools that allow the study of the structural and functional evolution of this system in reptiles. By employing RT-PCR and RACE, the cDNAs encoding for GHRH, PACAP, TRH, SST and IGF1 were amplified and sequenced. Results showed that these cDNAs coded for the corresponding protein precursors of 154, 170, 243, 113, and 131 amino acids, respectively. Of these, GHRH, PACAP, SST and IGF1 precursors exhibited a high structural conservation with respect to its counterparts in other vertebrates. On the other hand, iguana's TRH precursor showed 7 functional copies of mature TRH (pyr-QHP-NH ), as compared to 4 and 6 copies of TRH in avian and mammalian proTRH sequences, respectively. It was found that in addition to its primary production site (brain for GHRH, PACAP, TRH and SST, and liver for IGF1), they were also expressed in other peripheral tissues, i.e. testes and ovaries expressed all the studied mRNAs, whereas TRH and IGF1 mRNAs were observed ubiquitously in all tissues considered. These results show that the main SA components in reptiles of the Squamata Order maintain a good structural conservation among vertebrate phylogeny, and suggest important physiological interactions (endocrine, autocrine and/or paracrine) between them due to their wide peripheral tissue expression. [Mh] Termos MeSH primário: Hormônio Liberador de Hormônio do Crescimento/genética Iguanas/genética Fator de Crescimento Insulin-Like I/genética Polipeptídeo Hipofisário Ativador de Adenilato Ciclase/genética Somatostatina/genética Hormônio Liberador de Tireotropina/genética [Mh] Termos MeSH secundário: Sequência de Aminoácidos Animais Sequência de Bases Hormônio Liberador de Hormônio do Crescimento/química Hormônio Liberador de Hormônio do Crescimento/metabolismo Fator de Crescimento Insulin-Like I/química Fator de Crescimento Insulin-Like I/metabolismo Filogenia Polipeptídeo Hipofisário Ativador de Adenilato Ciclase/química Polipeptídeo Hipofisário Ativador de Adenilato Ciclase/metabolismo RNA Mensageiro/genética RNA Mensageiro/metabolismo Somatostatina/química Somatostatina/metabolismo Hormônio Liberador de Tireotropina/química Hormônio Liberador de Tireotropina/metabolismo [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Pituitary Adenylate Cyclase-Activating Polypeptide); 0 (RNA, Messenger); 51110-01-1 (Somatostatin); 5Y5F15120W (Thyrotropin-Releasing Hormone); 67763-96-6 (Insulin-Like Growth Factor I); 9034-39-3 (Growth Hormone-Releasing Hormone) [Em] Mês de entrada: 1802 [Cu] Atualização por classe: 180216 [Lr] Data última revisão: 180216 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 171005 [St] Status: MEDLINE

3 / 18411

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28467898 [Au] Autor: Melzer S; Gil M; Koser DE; Michael M; Huang KW; Monyer H [Ad] Endereço: Department of Clinical Neurobiology at the Medical Faculty of Heidelberg University and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. [Ti] Título: Distinct Corticostriatal GABAergic Neurons Modulate Striatal Output Neurons and Motor Activity. [So] Source: Cell Rep;19(5):1045-1055, 2017 May 02. [Is] ISSN: 2211-1247 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: The motor cortico-basal ganglion loop is critical for motor planning, execution, and learning. Balanced excitation and inhibition in this loop is crucial for proper motor output. Excitatory neurons have been thought to be the only source of motor cortical input to the striatum. Here, we identify long-range projecting GABAergic neurons in the primary (M1) and secondary (M2) motor cortex that target the dorsal striatum. This population of projecting GABAergic neurons comprises both somatostatin-positive (SOM ) and parvalbumin-positive (PV ) neurons that target direct and indirect pathway striatal output neurons as well as cholinergic interneurons differentially. Notably, optogenetic stimulation of M1 PV and M2 SOM projecting neurons reduced locomotion, whereas stimulation of M1 SOM projecting neurons enhanced locomotion. Thus, corticostriatal GABAergic projections modulate striatal output and motor activity. [Mh] Termos MeSH primário: Corpo Estriado/fisiologia Neurônios GABAérgicos/metabolismo Atividade Motora [Mh] Termos MeSH secundário: Animais Neurônios Colinérgicos/metabolismo Neurônios Colinérgicos/fisiologia Corpo Estriado/citologia Corpo Estriado/metabolismo Vias Eferentes/metabolismo Vias Eferentes/fisiologia Neurônios GABAérgicos/fisiologia Interneurônios/metabolismo Interneurônios/fisiologia Masculino Camundongos Parvalbuminas/genética Parvalbuminas/metabolismo Somatostatina/genética Somatostatina/metabolismo [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Parvalbumins); 51110-01-1 (Somatostatin) [Em] Mês de entrada: 1802 [Cu] Atualização por classe: 180213 [Lr] Data última revisão: 180213 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170504 [St] Status: MEDLINE

4 / 18411

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 29211787 [Au] Autor: Han X; Xu Z; Cao S; Zhao Y; Wu W [Ad] Endereço: Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. [Ti] Título: The effect of somatostatin analogues on postoperative outcomes following pancreatic surgery: A meta-analysis. [So] Source: PLoS One;12(12):e0188928, 2017. [Is] ISSN: 1932-6203 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: BACKGROUND: Leakage from the pancreatic stump is a leading cause of morbidity following pancreatic surgery. It is essential to evaluate the effect of somatostatin analogues (SAs) following pancreatic surgery by analyzing all recent clinical trials. DATA SOURCES: We performed a literature search in the Medline, EMBASE, Cochrane Central Register of Controlled Trials and Web of Science databases up to May 29, 2016. Publication bias was assessed with Egger's test. Study quality was assessed using the Jadad Composite Scale. CONCLUSIONS: Twelve clinical trials involving 1703 patients from Jan 1st, 2000 to May 29th, 2016 were included in the study. With improvements in surgical management and peri-operative patient care, prophylactic use of somatostatin and its analogues reduced the overall incidence of pancreatic fistulas (RR 0.72, 95% CI 0.55-0.94; p = 0.02) and decreased the post-operative hospital stay after pancreatic surgery (the weighted mean difference was -1.06, 95% CI-1/88 to -0.23; p = 0.01). Other post-operative outcomes did not change significantly with the use of somatostatin analogues. [Mh] Termos MeSH primário: Pâncreas/cirurgia Somatostatina/administração & dosagem [Mh] Termos MeSH secundário: Seres Humanos Resultado do Tratamento [Pt] Tipo de publicação: JOURNAL ARTICLE; META-ANALYSIS [Nm] Nome de substância: 51110-01-1 (Somatostatin) [Em] Mês de entrada: 1712 [Cu] Atualização por classe: 171229 [Lr] Data última revisão: 171229 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 171207 [St] Status: MEDLINE [do] DOI: 10.1371/journal.pone.0188928

5 / 18411

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28993415 [Au] Autor: Dal J; Klose M; Heck A; Andersen M; Kistorp C; Nielsen EH; Bollerslev J; Feldt-Rasmussen U; Jørgensen JOL [Ad] Endereço: Department of Endocrinology and Internal MedicineAarhus University Hospital, Aarhus, Denmark. [Ti] Título: Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study. [So] Source: Eur J Endocrinol;178(1):67-76, 2018 Jan. [Is] ISSN: 1479-683X [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: CONTEXT: Discordant GH and IGF-I values are frequent in acromegaly. The clinical significance and its dependence on treatment modality and of glucose-suppressed GH (GH ) measurements remain uncertain. OBJECTIVE: To evaluate the effects of targeting IGF-I GH during somatostatin analogue (SA) treatment. PATIENTS AND METHODS: 84 patients with controlled acromegaly after surgery ( = 23) or SA ( = 61) underwent a GH profile including an OGTT, at baseline and after 12 months. SA patients were randomized to monitoring according to either IGF-I ( = 33) or GH ( = 28). SA dose escalation was allowed at baseline and 6 months. MAIN OUTCOME MEASURES: GH and IGF-I at baseline and 12 months, and disease-specific Quality of Life (QoL). RESULTS: IGF-I and fasting GH levels were comparable between the surgery and the SA group, whereas GH (µg/L) was lower in the surgery group (GH 0.7 ± 0.1 vs 0.3 ± 0.1, < 0.01). SA dose increase was performed in 20 patients in the GH group and in 8 patients in the IGF-I group ( = 0.02), which increased the number of concordantly controlled patients ( = 0.01). QoL was only mildly affected at baseline in all groups and did not changed consistently during the study. CONCLUSION: (1) Discordant values in terms of high GH levels are prevalent in SA patients and more so if applying glucose-suppressed GH ; (2) targeting discordant levels of either GH or IGF-I translates into SA dose increase and improved biochemical control; (3) even though QoL was not improved in this study, we suggest biochemical assessment of disease activity to include glucose-suppressed GH also in SA patients. [Mh] Termos MeSH primário: Acromegalia/sangue Acromegalia/tratamento farmacológico Sistemas de Liberação de Medicamentos/métodos Hormônio do Crescimento Humano/sangue Fator de Crescimento Insulin-Like I/metabolismo Somatostatina/análogos & derivados [Mh] Termos MeSH secundário: Adulto Feminino Seres Humanos Masculino Meia-Idade Estudos Prospectivos Método Simples-Cego Somatostatina/administração & dosagem Resultado do Tratamento [Pt] Tipo de publicação: JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL [Nm] Nome de substância: 12629-01-5 (Human Growth Hormone); 51110-01-1 (Somatostatin); 67763-96-6 (Insulin-Like Growth Factor I) [Em] Mês de entrada: 1711 [Cu] Atualização por classe: 171128 [Lr] Data última revisão: 171128 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 171011 [St] Status: MEDLINE [do] DOI: 10.1530/EJE-17-0546

6 / 18411

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28965758 [Au] Autor: Miao C; Cao Q; Moser MB; Moser EI [Ad] Endereço: Kavli Institute for Systems Neuroscience and Centre for Neural Computation, Norwegian University of Science and Technology, Olav Kyrres Gate 9, MTFS, 7489 Trondheim, Norway. [Ti] Título: Parvalbumin and Somatostatin Interneurons Control Different Space-Coding Networks in the Medial Entorhinal Cortex. [So] Source: Cell;171(3):507-521.e17, 2017 Oct 19. [Is] ISSN: 1097-4172 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: The medial entorhinal cortex (MEC) contains several discrete classes of GABAergic interneurons, but their specific contributions to spatial pattern formation in this area remain elusive. We employed a pharmacogenetic approach to silence either parvalbumin (PV)- or somatostatin (SOM)-expressing interneurons while MEC cells were recorded in freely moving mice. PV-cell silencing antagonized the hexagonally patterned spatial selectivity of grid cells, especially in layer II of MEC. The impairment was accompanied by reduced speed modulation in colocalized speed cells. Silencing SOM cells, in contrast, had no impact on grid cells or speed cells but instead decreased the spatial selectivity of cells with discrete aperiodic firing fields. Border cells and head direction cells were not affected by either intervention. The findings point to distinct roles for PV and SOM interneurons in the local dynamics underlying periodic and aperiodic firing in spatially modulated cells of the MEC. VIDEO ABSTRACT. [Mh] Termos MeSH primário: Córtex Entorrinal/citologia Interneurônios/metabolismo Parvalbuminas/metabolismo Somatostatina/metabolismo Processamento Espacial [Mh] Termos MeSH secundário: Animais Neurônios GABAérgicos/metabolismo Células de Grade/citologia Masculino Camundongos Camundongos Endogâmicos C57BL Vias Neurais [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Parvalbumins); 51110-01-1 (Somatostatin) [Em] Mês de entrada: 1711 [Cu] Atualização por classe: 171101 [Lr] Data última revisão: 171101 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 171003 [St] Status: MEDLINE

7 / 18411

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28923213 [Au] Autor: Enzler T; Fojo T [Ad] Endereço: Department of Medicine, Division of Hematology Oncology, Columbia University, New York, NY. [Ti] Título: Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors. [So] Source: Semin Oncol;44(2):141-156, 2017 Apr. [Is] ISSN: 1532-8708 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: Neuroendocrine tumors (NETs) are a relatively rare and heterogeneous group of neoplasms with an annual incidence of ~35 cases per 100,000 people in the United States. The updated World Health Organization (WHO) classification system of gastroenteropancreatic (GEP)-NETs categorizes these tumors according to site of origin, clinical syndrome, and degree of differentiation. Well-differentiated NETs arising from the gastrointestinal tract or lungs (formerly known as carcinoid tumors) are often indolent and slow-growing. In contrast, poorly differentiated neuroendocrine carcinomas (NECs) are aggressive and have a poor prognosis. Due to their insidious onset, most NETs are diagnosed at an advanced stage and a curative approach is not possible. In these patients, medical therapy is limited to disease control, including relief of symptoms that arise from overproduction of peptide hormones by the tumors. Somatostatin analogues (SSAs) have remained the mainstay of symptoms control. In addition to symptoms control, clinical data also support an anti-proliferative effect of SSAs in patients with well- to moderately differentiated NETs. Long-acting SSAs have greatly facilitated their use. This review will focus on two long-acting SSAs, octreotide LAR and lanreotide, and their use in the clinical setting. Information necessary to assess their relative merits is summarized. We conclude these two therapies are interchangeable making value a very important consideration in their use. [Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico Tumores Neuroendócrinos/tratamento farmacológico Octreotida/uso terapêutico Peptídeos Cíclicos/uso terapêutico Somatostatina/análogos & derivados [Mh] Termos MeSH secundário: Antineoplásicos/administração & dosagem Preparações de Ação Retardada Seres Humanos Tumores Neuroendócrinos/patologia Octreotida/administração & dosagem Peptídeos Cíclicos/administração & dosagem Somatostatina/administração & dosagem Somatostatina/uso terapêutico [Pt] Tipo de publicação: JOURNAL ARTICLE; REVIEW [Nm] Nome de substância: 0 (Antineoplastic Agents); 0 (Delayed-Action Preparations); 0 (Peptides, Cyclic); 0G3DE8943Y (lanreotide); 51110-01-1 (Somatostatin); RWM8CCW8GP (Octreotide) [Em] Mês de entrada: 1709 [Cu] Atualização por classe: 170928 [Lr] Data última revisão: 170928 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170920 [St] Status: MEDLINE

8 / 18411

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28922851 [Au] Autor: Mehta RI; Tsymbalyuk N; Ivanova S; Stokum JA; Woo K; Gerzanich V; Simard JM [Ad] Endereço: Department of Pathology and Laboratory Medicine; Center for Neurotherapeutics Discovery, Department of Neuroscience; Center for Translational Neuromedicine, University of Rochester, Rochester, New York; Department of Pathology; Department of Neurosurgery; Department of Physiology, University of Mary [Ti] Título: α-Endosulfine (ARPP-19e) Expression in a Rat Model of Stroke. [So] Source: J Neuropathol Exp Neurol;76(10):898-907, 2017 10 01. [Is] ISSN: 1554-6578 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: In nutrient restricted environments, the yeast endosulfines Igo1/2 are activated via TORC1 inhibition and function critically to initiate and coordinate the cellular stress response that promotes survival. We examined expression of αEnsa, the mammalian homolog of yeast endosulfines, in rat stroke. Prominent neuronal upregulation of αEnsa was identified in 3 patterns within the ischemic gradient: (1) neurons in GFAP-/HSF1+ cortex showed upregulation and near-complete nuclear translocation of αEnsa protein within hours of ischemic onset; (2) neurons in GFAP+/HSF1+ cortex showed upregulation in cytoplasm and nuclei that persisted for days; (3) neurons in GFAP+/HSF1- cortex showed delayed cytosolic-only upregulation that persisted for days. Findings were corroborated using in situ hybridization for ENSA mRNA. Rapamycin treatment was found to reduce infarct size and behavioral deficits and, in GFAP+/HSF1+ zones, enhance αEnsa neuronal nuclear translocation and mitigate cell death, relative to controls. Based on the conservation of TOR signaling across species, and on the finding that the Rim15-Igo1/2-PP2A module is triggered by substrate deprivation in eukaryotic yeast, we speculate that αEnsa is activated by substrate deprivation, functioning through the homologous MASTL-αEnsa/ARPP19-PP2A module to promote neuronal survival. In conjunction with recent studies suggesting a neuroprotective role, our data highlight a potential function for αEnsa within ischemic brain. [Mh] Termos MeSH primário: Encéfalo/patologia Regulação da Expressão Gênica/fisiologia Neurônios/metabolismo Peptídeos/metabolismo Acidente Vascular Cerebral/patologia [Mh] Termos MeSH secundário: Animais Encéfalo/metabolismo Infarto Encefálico/tratamento farmacológico Infarto Encefálico/patologia Moléculas de Adesão Celular/metabolismo Chaperonina 60/metabolismo Modelos Animais de Doenças Regulação da Expressão Gênica/efeitos dos fármacos Seres Humanos Imunossupressores/farmacologia Masculino Proteínas Mitocondriais/metabolismo Proteínas do Tecido Nervoso/metabolismo Neurônios/efeitos dos fármacos Peptídeos/genética Molécula-1 de Adesão Celular Endotelial de Plaquetas/metabolismo Ratos Ratos Wistar Sirolimo/farmacologia Somatostatina/metabolismo Acidente Vascular Cerebral/tratamento farmacológico Acidente Vascular Cerebral/fisiopatologia Fatores de Tempo [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Cell Adhesion Molecules); 0 (Chaperonin 60); 0 (Esam protein, rat); 0 (Hspd1 protein, rat); 0 (Immunosuppressive Agents); 0 (Mitochondrial Proteins); 0 (Nerve Tissue Proteins); 0 (Peptides); 0 (Platelet Endothelial Cell Adhesion Molecule-1); 0 (endosulfine); 51110-01-1 (Somatostatin); W36ZG6FT64 (Sirolimus) [Em] Mês de entrada: 1710 [Cu] Atualização por classe: 171116 [Lr] Data última revisão: 171116 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170920 [St] Status: MEDLINE [do] DOI: 10.1093/jnen/nlx074

9 / 18411

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28904697 [Au] Autor: Anoun N; El Ouahabi H [Ad] Endereço: Service d'Endocrinologie, Diabétologie et Nutrition, CHU Hassan II de Fès, Maroc. [Ti] Título: [Acromegaly features in the aging population]. [Ti] Título: L'acromégalie du sujet âgé: quelles particularités?. [So] Source: Pan Afr Med J;27:169, 2017. [Is] ISSN: 1937-8688 [Cp] País de publicação: Uganda [La] Idioma: fre [Ab] Resumo: Somatotroph adenomas are rare in the aging population. Diagnosis of somatotroph adenomas is often long delayed and they are characterized by atypical clinical picture. Their diagnostic criteria are similar to those used for younger patients. Surgery, if possible, is the treatment of choice for acromegaly in the elderly. Somatostatin analogues have shown to be effective in these patients. Prognosis is inversely correlated with patient's age, duration of disease and last GH level under treatment. Beside evolution of disease, age is a major determinant of mortality. We report three cases of elderly patients with acromegaly aged 75, 70 and 66 years respectively with a literature review. [Mh] Termos MeSH primário: Acromegalia/diagnóstico Hormônio do Crescimento/metabolismo Somatostatina/administração & dosagem [Mh] Termos MeSH secundário: Acromegalia/patologia Acromegalia/terapia Fatores Etários Idoso Feminino Seres Humanos Prognóstico [Pt] Tipo de publicação: CASE REPORTS; JOURNAL ARTICLE; REVIEW [Nm] Nome de substância: 51110-01-1 (Somatostatin); 9002-72-6 (Growth Hormone) [Em] Mês de entrada: 1709 [Cu] Atualização por classe: 170922 [Lr] Data última revisão: 170922 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170915 [St] Status: MEDLINE [do] DOI: 10.11604/pamj.2017.27.169.11518

10 / 18411

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28859333 [Au] Autor: Flores-Cuadrado A; Ubeda-Bañon I; Saiz-Sanchez D; Martinez-Marcos A [Ad] Endereço: Laboratorio de Neuroplasticidad y Neurodegeneración, Facultad de Medicina de Ciudad Real, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha, Ciudad Real, Spain. [Ti] Título: α-Synucleinopathy in the Human Amygdala in Parkinson Disease: Differential Vulnerability of Somatostatin- and Parvalbumin-Expressing Neurons. [So] Source: J Neuropathol Exp Neurol;76(9):754-758, 2017 Sep 01. [Is] ISSN: 1554-6578 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: Olfactory dysfunction and emotional impairment are nonmotor symptoms in Parkinson disease (PD). These symptoms might be correlated with the appearance of Lewy bodies and neurites (ubiquitin and α-synuclein aggregates) in the amygdala (Braak stage 3). α-Synucleinopathy in the amygdala has been studied only occasionally, and no data on cell types involved are available. This work aimed to analyze α-synuclein expression in the basolateral, central, and cortical amygdaloid nuclei in 5 PD patients (Braak stages 3-5) and 5 controls. Expression of somatostatin and parvalbumin as well as its colocalization with α-synuclein was quantified under confocal microscopy. α-synuclein expression did not differ significantly between the central and other nuclei. The density of somatostatin was significantly decreased in the basolateral and central complex. The density of parvalbumin was significantly diminished in the basolateral complex. Parvalbumin-positive cells colocalized frequently with α-synuclein (68.44%), whereas, somatostatin-positive cells colocalized only occasionally (6.98%). These data revealed the differential vulnerability among interneuron populations in the human amygdala and could help to explain nonmotor symptoms such as anhedonia in PD. [Mh] Termos MeSH primário: Tonsila do Cerebelo/patologia Neuritos/patologia Doença de Parkinson/patologia Parvalbuminas/metabolismo Somatostatina/metabolismo alfa-Sinucleína/metabolismo [Mh] Termos MeSH secundário: Idoso Idoso de 80 Anos ou mais Tonsila do Cerebelo/metabolismo Diagnóstico Feminino Seres Humanos Corpos de Lewy/metabolismo Corpos de Lewy/patologia Masculino Meia-Idade Neuritos/metabolismo Ubiquitina/metabolismo [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Parvalbumins); 0 (Ubiquitin); 0 (alpha-Synuclein); 51110-01-1 (Somatostatin) [Em] Mês de entrada: 1709 [Cu] Atualização por classe: 170918 [Lr] Data última revisão: 170918 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170902 [St] Status: MEDLINE [do] DOI: 10.1093/jnen/nlx054

---

página 1 de 1842

ir para página

Refinar a pesquisa

Base de dados : MEDLINE

Formulário avançado

		Pesquisar	no campo
1			PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2
2	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2
3	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde